On March 20, 2021 BioEclipse Therapeutics (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, reported that Pam Contag, Ph.D., President and Chief Executive Officer of BioEclipse, will present at the Spring 2021 virtual meeting of the Oncology Investor Conference, sponsored by the National Foundation for Cancer Research, taking place March 29, 2021 to April 1, 2021 (Press release, BioEclipse Therapeutics, MAR 29, 2021, View Source [SID1234577301]). The virtual presentation will be available for all registered attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Dr. Contag will provide an overview of BioEclipse’s business and recent achievements, as well as the company’s clinical program for its lead drug candidate, CRX100. BioEclipse has initiated an open-label, Phase 1, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetic (PK) properties of CRX100 in advanced solid tumors that do not respond to standard of care, including triple-negative breast cancer, colorectal cancer, hepatocellular carcinoma, osteosarcoma, epithelial ovarian cancer, and gastric cancer.

Members of the BioEclipse management team will also be available to participate in virtual one-on-one meetings with investors and who are registered to attend the conference. Following the conclusion of the event, a recording of Dr. Contag’s presentation will be available under "Recent Presentations" in the Investors section of the Company’s website at www.cytocom.com.